Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ready to pop...multi-month wedge breakout.
Down 35 of last 50 days. Culley planning next offering for one last fleece.
Very bad close today, again still up after hours, can't maintain any pulse...
still waiting and hold.
gl
To bad Cully still at helm. Once he is gone stock will prosper ... not until.
"Blue angel loves mast therapeutics"
Remember it?
I still receive mails with advices of price target of at least 2,5$ within 12 month! (and without R/S)LOL
I can't believe my eyes that we're back to 10's!
what an awful chart now,this is pure manipulation to me.
Look at the 0,115 spike in after hours, is this a clue?
AIMO,of course
To all the bozos on this board who avg down .. never avg down in a penny stock you buy it once because you think it's a bottom period!
Baker bros. NY huge tute sold out 8.4 million shares ! You people should all do the same cut your loses . Buy a proven company ! Don't be a penny ante pipe dreamer !
Will Savara have rights to the past failures of drug test from MAST? Two of the 5 failures in the last 7 years had the potential with proper testing procedures to be a success. IMO the CEO had no clue on procedural methods which unfortunately lead to failures. Thanks ....
News out. MSTX announced today it has set a date for a special meeting of its stockholders to vote on matters related to the proposed merger with Savara Inc. (Savara), a privately-held, clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases.
The special meeting will be held at 9:00 a.m., local time, on April 21, 2017 at 3611 Valley Centre Drive, Suite 500, San Diego, California 92130. Mast's stockholders of record as of the close of business on March 13, 2017 are entitled to receive notice of, and to vote at, the special meeting.
The merger has been unanimously approved by the boards of directors of both companies and the board of directors of Mast unanimously recommends that its stockholders vote "FOR" the special meeting proposals described in the proxy statement/prospectus/information statement declared effective by the Securities and Exchange Commission on March 15, 2017, a copy of which will be provided to Mast stockholders of record as of March 13, 2017. The proposed merger is expected to close promptly after the Mast special meeting scheduled for April 21, 2017, subject to the approval of the stockholders of each company and the satisfaction or waiver of the other closing conditions in the merger agreement between the companies.
The combined company would advance a pipeline of novel inhalation therapies for the treatment of diseases with significant unmet medical needs, featuring three product candidates, each in advanced stages of clinical development:
-- AeroVanc, an inhaled dry-powder vancomycin to treat chronic methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection in cystic fibrosis (CF) in preparation for a pivotal Phase 3 study;
-- Molgradex, an inhaled nebulized GM-CSF to treat pulmonary alveolar proteinosis (PAP) currently in Phase 2/3 development; and
-- AIR001, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction (HFpEF) currently in Phase 2 development.
Select Anticipated Upcoming Development Milestones
-- Closing of proposed merger in Q2/2017.
-- Initiate a pivotal Phase 3 study of AeroVanc in Q3/2017.
-- Complete negotiations with the U.S. Food and Drug Administration (FDA) on the requirements for a pivotal clinical study of Molgradex in the U.S. in Q3/2017.
-- Announce strategy related to Molgradex program expansion for the treatment of a rare lung infection in 2017.
-- Announce top-line results from Phase 2/3 study of Molgradex, expected to be registration-enabling for the treatment of PAP in Europe and Japan, in Q1/2018.
-- Announce results from ongoing Phase 2 study of AIR001 for the treatment of HFpEF being conducted by the Heart Failure Clinical Research Network in Q1/2018.
If you guys want out - wait till Blue shows back up. He is a pump and dump monkey. When he shows up he is pumping, then sells and goes away. Surely you guys have seen this already. When he shows up SELL shortly after. He is probably buying now.
ANX OR Mast is my worst pick in last 7 years. The most poorly managed bio company for shareholders in existence. RS, dilution, offering, management bonuses have made your $100 now .10 cents. Make matters worse successful bio companies every day showing how to advance drugs with strong aggressive CEO's. Not here ... 5 drugs in 7 years all failures. Sadly managed .... pathetic.
What a scam could see 9s here soon $mstx
Baker bros NY instution got crushed in last 2 years on pharma phase III results ex. THLD, XOMA, MSTX etc etc etc
last Savara-Mast presentation was focused only about CF and pulmonary diseases, it seems like the newco is a CF company.
IMO I think that AIR001 will go the other direction, maybe with a big Co. collaboration.
Just an hope
I see successful testing on different drugs every day. You wonder what MAST could have been with a qualified CEO. Cully had five prominent drugs in 7 years and botched the testing on all seven of them. Good ridden's at merger. New management would never allow that to happen.
per S4 10 Feb. 2017, pag.31 pdf:
As of February 2, 2017, Mast had an outstanding principal balance of $3.1 million under its debt facility with Hercules Capital, Inc. and Hercules
Technology III, L.P. (collectively referred to as Hercules) that is
secured by a lien covering substantially all of Mast’s assets, excluding intellectual property, but including proceeds from the sale, licensing or disposition of Mast’s intellectual property.
....
The loan would remain in place upon its existing terms, including the January 1, 2019 scheduled maturity date.
The terms are that they must be able to raise some cash 4-6 millions by April 30 and Savara must raise at least 20 mil by August 31, 2017
In other words Hercules controls Mast's assets until merger and, after the merger, they demand a minimal cash supply as guarantee to maintain the loan.
My free interpretation
Looks like Cully never paid up(figures) and just extended it.
Savara Inc. mentioned at least 7 times in contract.
Sure they knew they would never get money out of Cully anyway.
SECTION 4. Amendments to Loan Agreement. Subject to all of the terms and conditions set forth in this Amendment, Borrower, Agent and Lender hereby agree to the following amendments to the Loan Agreement.
(A) The Loan Agreement is hereby amended by adding a new Section 7.17 to the Loan Agreement, such section to read as follows:
“7.17Cash Covenant.
(a)Borrower shall, at all times from and after the Effective Time under that certain Agreement and Plan of Merger and Reorganization, dated January 6, 2017, among Borrower, Victoria Merger Corp., a Delaware corporation, and Savara Inc., a Delaware corporation (“Savara”), maintain in one or more U.S.-domiciled accounts in the name of Borrower and subject to an Account Control Agreement unrestricted cash equal to at least $4,000,000 (the “Minimum Cash Amount”); provided, however, (i) the Minimum Cash Amount shall be reduced to $2,000,000 upon Borrower’s achievement of the First Financing Milestone, and (ii) if Borrower achieves the Second Financing Milestone, the cash covenant set forth in this Section 7.17 shall not apply to Borrower from and after the date the Second Financing Milestone is achieved.
(b)For purposes of the Agreement:
(i)
“First Financing Milestone” means the receipt by Borrower, a Qualified Subsidiary and/or Savara of aggregate net cash proceeds of at least $6,000,000 from the sale and issuance of equity securities and/or Qualified Indebtedness (or a combination thereof) after January 6, 2017 and on or before April 30, 2017.
(ii)
“Qualified Indebtedness” means (x) Subordinated Indebtedness of Borrower and its Qualified Subsidiaries and (y) Subordinated Indebtedness or Indebtedness of Savara; provided that any Indebtedness incurred by Savara prior to the Effective Time that is not Subordinated Indebtedness shall only constitute “Qualified Indebtedness” if such Indebtedness is subject to a subordination agreement (in a form acceptable to Agent) that will result in such Indebtedness becoming Subordinated Indebtedness immediately upon the Effective Time without any further action required on the part of the applicable lender(s).
(iii)
“Second Financing Milestone” means the receipt by Borrower, a Qualified Subsidiary and/or Savara of aggregate net cash proceeds of at least $20,000,000 from any or all (including any combination thereof) of (x) the sale and issuance of equity securities and/or Qualified Indebtedness and/or (y) the receipt of financing from such other financing sources (including grant amounts) approved by Agent in its reasonable discretion, and in each case to the extent actually received by Borrower, a Qualified Subsidiary or Savara after January 6, 2017 and on or prior to August 31, 2017 (it being agreed that (A) grant amounts shall be considered actually received if such amounts are fully-committed, irrevocable and scheduled to be funded during 2017 and (B) the aggregate net cash proceeds of any offering that satisfies the requirements of the First Financing Milestone shall be counted in determining whether the Second Financing Milestone has been met).”
He is just trying to avoid lawsuits which may still be to come. The sooner he resigns the better. The guy is the pus in a zit, the cancer in a tumor. Sooner the excretion is disinfected the better for investors.
Financials pathetic just like his management judgements.
"-0.02$ in place of -0.06$ one year ago, pps tanked from 0.50$ to 0.11$ and -6% today... What's wrong here?
I saw 0.13$ pre-market but...No.
Sold 15,000 yesterday @0.12$
hold 180,000. GL
new Hercules loan agreement.
Signed March 3, is it a new loan with Savara?
https://www.lawinsider.com/contracts/1jdcxwJbogvs1Pflz3g8Bd/adventrx-pharmaceuticals-inc/1160308/2017-03-06
MAST Investor presentation is all focused on Savara drugs and trials. It seems that AIR001, a potential blockbuster in HF, is nearly missing , oly interested in the new application on Cystic Fibrosis against lung infection of P. Aeureginosa. A complementary drug in Savara pipeline.
I'm disappointed about this , because Mast's pipeline value is just alike that of Savara.
Culley has once again revealed his true colours as an inept CEO, that wasted money of his investors for years and years , even unable to carry out a fair merger.
It's better to vote NO at the merger.
http://seekingalpha.com/article/4052271-mast-therapeutics-mstx-investor-presentation-slideshow
MSTX NEWS 3-6-17
-->Mast Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
http://seekingalpha.com/pr/16762681-mast-therapeutics-reports-fourth-quarter-full-year-2016-financial-results
"The Company's net loss for the fourth quarter of 2016 was $6.0 million, or $0.02 per share (basic and diluted), compared to a net loss of $10.2 million, or $0.06 per share (basic and diluted), for the same period in 2015."
-->Mast Therapeutics (MSTX) Confirms Clinical Study Of AIR001 For Treatment Of Chronic Infection In Cystic Fibrosis Patients
https://www.streetinsider.com/dr/news.php?id=12632742&gfv=1
Mast Therapeutics, Inc. (NYSE: MSTX) today reported that its wholly-owned subsidiary, Aires Pharmaceuticals, Inc., has entered into an agreement with the University of Pittsburgh related to a Phase 1/2 open-label safety and proof of concept clinical trial of the Company's lead product candidate, AIR001, for the treatment of Pseudomonas aeruginosa (P. aeruginosa) infection in cystic fibrosis (CF) patients. The study is being conducted by the University of Pittsburgh and the University of Pittsburgh Medical Center. Mast's subsidiary will provide study drug and nebulizers for the study, but no direct financial support.
.13 break sends is...
good news for MSTX
http://masttherapeutics.com/investors/news/?releaseid=2251635
thank you for your in put make glty
Can not wait till Cully gone for good. As long as he is CEO this will not move. Investors know because of his countless failures and deceptions stock can not win. As soon as it turns over then patient investors knowing no more deception from Cully, will buy.
Damn! that dirty gap is filled, 0,106 touched then rebound.
All those trade bots are junk sh*t.
Just my opinion, i'm angry that i've predicted this case but not played it... My fault
GL now it will explode...
Now hold 195,000 shares
The Bottom is in today .10 higher now when I bought .09 5 weeks ago
What a scam should see 10s here soon $mstx
tinylion, Thank you for doing those calculations/projections.
I was right the first time 100000 shares at the exch of 46.92 will always leave you with 2131 shares. if r/s at 38:1 happens than you would use exch rate of 1.23 and still have 2131 shares at 4.25 sorry for any confusion.
correction to previous post at the 1.24 exchange you would have 213 shares at $4.25 not 2131
I've spent a fair amount of time on the S4. MAST evaluation for calculation of the exchange ratio is .09-.10. My belief is that the sequence of events will be as follows...
Vote to merge will be yes, est. 872million shares issued to pay Savara common stockholders $4.22-4.25 per share for 20,520 shares and the existing outstanding shares of around 262M will be used to purchase 6,480,000 SAV shares to give MAST holders their 24% of SAVARA. The exchange ratio is stated in the S4 at 46.92 shares of MSTX for 1 share of Savara.
If you own MSTX for around .09-.10 then you got equal value for your shares if you own for more then you pay more than $4.25 per share and if you own for less you got a deal and paid less per share. EX. 10000 shares of Mast gets 213 shares of SAV no matter what you own MAST for.
Reverse split will probably happen instantly upon signing as over 1 billion shares of MSTX on the market would probably cause share price to drop to .02-.03 per share. I'm guessing somewhere around 35-40 to 1 split ratio. Coincidently that range would make the share price acceptable to NYSE and put it right around 4.25 which is what MSTX holders paid for their shares. If that does happen the exchange ratio would be adjusted to about 1.24 MAST shares for 1 share of SAV. Your total cost doesn't change i.e. if you had 100000 MSTX at .0905 ( S4 ratio calc. number )at $9050 your 2131 shares of SAV would be 2131x$4.25 or $9050.
If the market see the value of the combined companies to be greater than the 4.25 valuation of Savara then you may be ahead if they disagree and think the initial evaluation of the two companies is less well...you know.
this stock is way over the market cap reverse is coming any thoughts on this ?
I believe that target price came before Cullys last drug failure in which he was predicting a 80% success rate. I hope you will see .20 cents before RS. Good luck ....
It's absolutely insane! Analyst said 2,5$ target but with a hold rating ??? how could you handle that? schizophrenia perhaps...
I Hold strong my shares,yes.
Anyone know if merger will include Epic re-evaluation? Seems new CEO has a track record of success and I would want to know why Epic failed and the possibility of re-testing.
Remember Cully has had 5 major drug possibilities with 5 failures. In last 8 years. Wonder if proper testing done if results would change. Know that success for Epic was at 80% before Cully said the testing had failed. After failure no real follow up why?
Yes, Trendy. Here's hoping we longs do well.
If it goes down i will buy more ... if not i wait for the pop :)! ... cool.
As long as you can swim with your head above water...lol
If deal goes through there will be a "short squeeze."
After RS happens about 75% of time. Then is chance to recover.
As a MSTX shareholder any position as long as Cully is out of here is good. Just as there are top CEO, Cully is considered as the dump at the bottom. .... and he has been that way for years.
Several years ago failed in one of 5 failed BIO tests. Never forget next quarter gave himself $175,000 bonus and options raise.
Picture beside word "scum" in Websters.
Is it such a good deal if your daughter has to pay 40 times the house's value? That's what's happening to Mast shareholders. Good for Savara investors if you are long MAST you will get diluted too far to see any real profit.
Look at it this way ...
If invested in Savara the company has doubled for shareholders in last 3 years. If in MSTX you lost half or more of investment.
My daughter buys foreclosed houses, puts a couple dollars in them and doubles her investment.
IMO Rob Neville sees a totally broken house that has the potential to double company value. That is what you have here.
I completely understand your concerns but feel Rob Neville track record clearly demonstrates his ability to enhance shareholder positions. Been about 90% accurate. You ask what about the other 10%? How can a guy of such transparency and integrity even be in the same room with a polar opposite(Cully CEO Of MSTX). Again you buy the worst house knowing it will double in value if properly managed.
He's doing great for savara investors Culley not so much for mast investors
I believe the one thing that has not been discussed that is foundational is management. Rob Neville the CEO of Savara will not do anything to his investors that will cause harm.
I have done some research on his past and the guy is "squicky clean" and has done nothing but enhanced shareholders positions. He is seeking a company to put Savara on the stock exchange.
When all the discussions are brought discussed you can not go wrong with that guy.
Rob Neville, Chairman and CEO of Savara added, “This merger is transformative for Savara and marks our second transaction in a year, each expanding Savara’s pipeline of inhaled therapies for serious and life-threatening diseases.
http://savarapharma.com/about-savara/management/
I fully understand a reverse split but an exchange ratio in a merger is not the same thing. You will be issued 1 share of the new company for whatever the final exchange ratio is regardless of the price.
The more MSTX is trading for the day of the merger the more you will pay
From investopedia
Example of Exchange Ratio
The exchange ratio in a merger or acquisition is the opposite of a fixed value deal in which a buyer offers a dollar amount to the seller, meaning that the number of shares or other assets backing the dollar value can fluctuate in an exchange ratio. For example, imagine that the buyer offers the seller 2 shares of the buyer's company in exchange for 1 share of the seller's company. Prior to the announcement of the deal, the buyer's shares may be trading at $10, while the seller's shares trade at $15. Due to the 2 to 1 exchange ratio, the buyer is effectively offering $20 for a seller share that is trading at $15.
Fixed exchange ratios are usually limited by caps and floors to reflect extreme changes in stock prices. Caps and floors prevent the seller from receiving significantly less consideration than anticipated, and they likewise prevent the buyer from giving up significantly more consideration than anticipated. Exchange ratios can also be accompanied by a cash component in a merger or acquisition, depending on the preferences of the companies involved in the deal.
Read more: Exchange Ratio Definition | Investopedia http://www.investopedia.com/terms/e/exchangeratio.asp#ixzz4YxstSuYF
Follow us: Investopedia on Facebook
There are so many factors it is almost impossible for a layperson to know unless all drug potentials formulated. Think this way ... You combine the values of the companies along with any outstanding debts.
Remember MSTX had no debt, in fact has over 20 million in cash to use on future testing. Along with this fact their loan drug is getting already about approximately 80% financed through the government.
Say MSTX has 200 million shares.
So you have 2000 shares of mstx at .20 cents values at $400
There is a 20/1 Reverse Split where now you have only 100 shares at $4.00 valued at a total of still $400.
Rather than 200 million shares there is only 20 million now.
If you have a private company and own one share of Savara at $4.00 you are voting on how many shares it increses (one now is 1.2, 1.5, 1.7?). So your $4.00 now $4.50 or $5.00.
You have 2 companies combining pipelines (MSTX 1, Savara 4) drug possibilities with market financing.
Followers
|
304
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
15766
|
Created
|
08/30/05
|
Type
|
Free
|
Moderators |
We are a publicly traded biopharmaceutical company headquartered in San Diego, California.
We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop vepoloxamer, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.
To learn more about our company, please see our Letter from the CEO.
http://www.masttherapeutics.com/investors/
Purpose
Condition | Intervention | Phase |
---|---|---|
Vaso-occlusive Crisis Sickle Cell Disease | Drug: Saline Drug: MST-188 | Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
Official Title: | Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis |
Estimated Enrollment: | 388 |
Study Start Date: | May 2013 |
Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: MST-188 MST-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours. | Drug: MST-188 Other Name: vepoloxamer |
Placebo Comparator: Saline Saline administered as a continuous infusion for up to 49 hours | Drug: Saline |
Ages Eligible for Study: | 4 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Mast Therapeutics CT.gov Call Center | 1-888-965-1238 |
Study Director: | Edwin L. Parsley, D.O. | Mast Therapeutics, Inc. |
Responsible Party: | Mast Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT01737814 History of Changes |
Other Study ID Numbers: | MST-188-01 |
Study First Received: | November 27, 2012 |
Last Updated: | September 24, 2015 |
Health Authority: | United States: Food and Drug Administration Belgium: Federal Agency for Medicines and Health Products, FAMHP Brazil: National Committee of Ethics in Research Dominican Republic: Consejo Nacional de Bioetica en Salud Jordan: Jordanian Food and Drug Administration Lebanon: Institutional Review Board Oman: Academic Accreditation Authority Panama: Ministry of Health Spain: Ministerio de Sanidad, Servicios Sociales e Igualdad Saudi Arabia: Saudi Food and Drug Administration Turkey: Drug and Medical Device Institution Jamaica: Ministry of Health |
sickle cell disease vaso-occlusive crisis |
Anemia, Sickle Cell Anemia Anemia, Hemolytic Anemia, Hemolytic, Congenital | Genetic Diseases, Inborn Hematologic Diseases Hemoglobinopathies |
MST-188 (purified poloxamer 188) is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. We initially are developing MST-188 as a treatment for complications arising from sickle cell disease.
AIR001 is a sodium nitrite solution for intermittent inhalation via nebulizer. Nitrite is a direct vasodilator and can be recycled in vivo to form nitric oxide (NO) independent of the classical NO synthase (NOS) pathway. Nitrite mediated NO formation has several beneficial effects, including dilation of blood vessels and reduction of inflammation and undesirable cell growth. Generation of NO from sodium nitrite is not dependent upon endothelial function and is enhanced in the setting of tissue hypoxia and acidosis, conditions in which NOS activity typically is depressed. In early clinical studies, AIR001 demonstrated positive hemodynamic effects with reductions observed in right atrial pressure and pulmonary capillary wedge pressure, as well as improvements in mean pulmonary artery pressures and cardiac output.
We are developing AIR001 for treatment of heart failure with preserved ejection fraction (HFpEF), a condition that affects millions in the U.S. and for which no proven therapeutic agent is available. Numerous lines of evidence suggest that HFpEF is a disease of NO deficiency. We are supporting two institution-sponsored Phase 2a studies in patients with HFpEF to evaluate acute hemodynamic effects of AIR001 and to evaluate its acute effects versus placebo on submaximal oxygen consumption and exercise hemodynamics.
AIR001 Inhalation Solution is sodium nitrite formulated with a phosphate buffer into an inhalation solution. Nitrite is a physiological signaling molecule with roles in intravascular endocrine nitric oxide (NO) production, hypoxic vasodilation, signaling, and cytoprotection after ischemia-reperfusion. Nitrite serves as the largest physiologic reservoir of NO and can be converted to NO independent of NO synthase (NOS) activity.
In experimental models, nitrite use demonstrated improved remodeling both in the pulmonary vasculature and right ventricle. Hemodynamic effects include venodilation with reductions in right atrial pressures, pulmonary and systemic vasodilation with reductions in pulmonary vascular resistance and left atrial pressures, and improved cardiac relaxation. In addition, recent clinical and nonclinical studies have demonstrated that nitrite can stimulate mitochondrial biogenesis and mitochondrial fusion and decrease mitochondrial oxygen consumption through a mechanism distinct from that of NO, which may have utility in treating heart failure.
We obtained the AIR001 program through our acquisition of Aires Pharmaceuticals, Inc. in February 2014. Prior to the acquisition, AIR001 had been tested in more than 120 healthy volunteers and patients with various forms of pulmonary hypertension in three Phase 1 studies and in one Phase 2 study in patients with pulmonary arterial hypertension. While the Phase 2 study was prematurely terminated due to Aires’ capital constraints prior to the acquisition, preliminary data from the study are positive, showing improvements in hemodynamic parameters and in exercise capacity from baseline. There were no treatment-related serious adverse events and methemoglobin levels remained normal (< 1.5%), which distinguishes AIR001 from safety concerns associated with intravenously-administered nitrite.
Data from these early clinical studies support continued clinical development of AIR001. Given the observed hemodynamic improvements of decreased right arterial pressure, decreased pulmonary capillary wedge (or left atrial pressure), as well as improvements in pulmonary vascular resistance and cardiac lusitropic effects, AIR001 may benefit patients with exercise impairment due to heart failure with preserved ejection fraction (HFpEF), for whom these are all desirable effects.
Hemodynamic improvements, improvements in pulmonary artery pressures, and cardiac lusitropic effects observed in earlier studies of AIR001 support AIR001’s potential to benefit patients with heart failure with preserved ejection fraction (HFpEF). We currently are pursuing clinical development of AIR001 for that patient population.
Event Timing
Initiate tQT/QTc Study Completed
Secure Orphan Designation for MST-188 for SCD in EU Completed
Activate First Site in Phase 3 Study Completed
File New Patent Applications Completed
Dose First Subject in Phase 3 Study Completed
Report data from tQT/QTc Study Q3 Completed and Primary Endpoints Met
Request Orphan Designation for MST-188 for ALI in U.S. Q3 Completed and Designation Granted By FDA
Initiate Nonclinical Proof-of-Concept Study in Heart Failure Q3 Completed and POC Data to be released Q1 '14
2014 Activities
Event Timing
Present Data From Nonclinical Proof-of-Concept Study In Heart Failure Q1 '14 Data Released 01/06/14'Showed Significant Statistical Improvement"
Initiate Phase 2 Study in ALI Q1 '14 Initiated
Outcome of review of application for Unique Name Designation For Purified Poloxamer 188 From U.S. Adopted Names Counsel Q1 '14 Granted and Named VEPOLOXAMER
Open First Ex-U.S. Clinical Sites in Phase 3 Trial Q1 '14. Initiated and On Schedule
Submit Abstract with Heart Failure Study Biomarker Data to Major Medical Conference Q2 '14
Request Orphan Designation for ALI in EU Q2 '14 Application Submitted
Initiate Nonclinical POC Study in Stroke Q2 '14 Study Initiated
Initiate EPIC Sub-Study Q2 '14 Initiated On Schedule 06/14/14
Report Results from Phase 2 Study of AIR001 in PAH Q3 '14 Positive Top line Data released 9/8/14
Initiate study with Dept of Defense: MST-188 Resuscitation from major trauma '14 CRADA with US Military Initiated Q3 '14
Receive protocol from FDA for Phase 2 Heart Failure Study Q4'14 FDA Approves Heart Failure Study 12/9/14
2015 Event Schedule
Initiate dosing Phase2a study in AIR001 Q1 '15. INITIATED 2/4/15
Nonclinical Study EMBOLIC STROKE Data Q1 '15: POSITIVE DATA RELEASED 2/11/15
Report nonclinical data for repeat dose on Vepoloxamer in Heart Failure Q1 '15 POSITIVE DATA RELEASE 03/02/15
Phase 2 Study HEART FAILURE Initiate Enrollment Q2 '15 INITIATED 3/23/15
EPIC EXTENSION STUDY (Repeat Exposure) Initiate Enrollment 1st Half '15 INITIATED 5/26/15
Phase 2a Study of AIR001 (WHO GROUP 2) in HFpEF Preliminary Data 2nd Half '15
Phase 2 Study Heart Failure Interim Safety Analysis 2nd Half '15
EPIC STUDY COMPLETE ENROLLMENT Q4 '15
2016 EVENTS
EPIC Top Line Data Q1 2016
Video of Management of Mast Therapeutics $MSTX speaking about MST-188 for Sickle Cell Disease ,orphan drug
http://www.youtube.com/watch?v=eI7inPOiyZM&feature=youtu.be
http://www.masttherapeutics.com/wp-content/uploads/2013/04/EPIC-An-Ongoing-Pivotal-Phase-3-Study-in-Patients-with-Sickle-Cell-Disease-Aug-21-2013.
Filing Company | Date of Filing | Total Reported Shares Owned | Shares Reported on 13F | |
---|---|---|---|---|
Baker Bros LLC | 12/31/14 | 4,774,434 | 4,774,434 | |
BVF Inc. | 3/31/15 | 7,241,600 | 7,241,600! | |
SC 13G | FRANKLIN RESOURCES INC | 02/04/15 | 11,946,100 | 11,946,100 |
Reported via | Event Date | Name | Ticker | Shares * | Change | % of Portfolio |
---|---|---|---|---|---|---|
13F MPM Asset Management | MSTX | 2,551,851 | ||||
13F Vanguard Group | MSTX | 3,382,483 |
http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=2&g=0&id=p32395513381
http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=9&g=0&id=p36778398928
http://stockcharts.com/freecharts/gallery.html?MSTX
P: 858-552-0866 F: 858-552-0876
General Inquiries
info@mastthera.com
Investor Relations Contact
ir@mastthera.com
Business Development Contact
busdev@mastthera.com
Careers Contact
hr@mastthera.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |